- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Trading below IPO price, and did get as high as $29 last July.
How much it's actually worth is hard to say with stocks this newly public, but insider trade is giving buy signals now so odds are good they share analyst confidence of this going from red ink to black this year.
Recs
Low-risk diversification strategy across multiple drugs.
Recs
Looks like its consolidating from the S&P downgrade. The price just moved above its 50 day lin reg line so I bet in a few weeks it will regress back to it.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 3 of 3